Noctrix Health is a Pleasanton, CA-based medical device company developing the Nidra Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS). Its flagship TOMAC therapy is a non-pharmacologic treatment intended to reduce symptoms of primary moderate-to-severe RLS and improve sleep quality in adults who are refractory to medications. Led by CEO and President Shri Raghunathan, the company focuses on clinically validated medical technologies to improve quality of life for patients with chronic medical conditions. Noctrix raised up to $33.5M in a financing that included both debt and equity. Backers included Blue Venture Fund and Sandbox Clinical Ventures. The company intends to use the funds to accelerate its U.S. commercial launch. Noctrix Health is a medical device company led by founder and CEO Shri Raghunathan that develops the Nidra™ Tonic Motor Activation (TOMAC) system, a non‑pharmacologic wearable intended to reduce symptoms of primary moderate‑severe Restless Legs Syndrome (RLS). The TOMAC system is designed to improve sleep quality in adults refractory to medications and is available in the US by prescription only. The company closed a $40M Series C financing to advance the therapy toward an anticipated US launch. Noctrix describes itself as committed to developing clinically validated medical technologies that improve quality of life for patients with chronic conditions. The new funding is intended to support regulatory and commercialization activities for the Nidra™ TOMAC therapy in the US.

Total raised

$74M

Funding rounds

3

Latest round

Equity

Latest activity

Sep 2025